Ganirelix: evidence, FDA status and research

It is an injection used in IVF to stop a woman ovulating too early. A trial of 313 women found pregnancy rates close to the older method, with fewer injections.

Sold for

Ganirelix is the IVF injection that stops the body ovulating before egg retrieval, replacing weeks of agonist down-regulation with a few days of antagonist.

Studies say

Randomized trials show pregnancy rates similar to the older leuprolide protocol with fewer injections, an A for its approved use.

Why grade A. Approval rested on randomized phase 3 trials against the standard long GnRH agonist protocol, including the North American trial cited here (313 women, ganirelix versus leuprolide), which found similar pregnancy rates with a shorter, simpler course. The label adds a 332-patient dose-finding trial and a larger open-label randomized trial against a GnRH agonist in which 463 women received ganirelix. ²⁴

FDA. Approved. Ganirelix acetate injection was approved by the FDA in 1999 (originally as Antagon, Organon) for inhibiting premature LH surges in women undergoing controlled ovarian stimulation for fertility treatment. It is sold in the US as ganirelix acetate injection by Organon and others, and as Fyremadel (Ferring); the Antagon name is no longer used. ¹³⁴

Written from 4 cited sources. Fact-checked 2026-10-27: 18 claims checked, 4 corrected. Last refreshed 2026-10-27. Not physician reviewed.

What this means for you

What people take it for: Stopping early ovulation during IVF
Can a US doctor prescribe it?: Yes, FDA approved for stopping early egg release during fertility treatment.
Properly tested in people?: Yes, in controlled trials, including one of 313 women.

Evidence checklist

Randomised controlled trial Randomized vs leuprolide protocolyes
Human study over 100 people North American trial, 313 womenyes
More than one research group North American and European trialsyes
Clinical outcomes, not surrogate markers Pregnancy rates measuredyes
Human safety data beyond case reports Birth anomaly rates similar to agonist cyclesyes

Drawn from the cited studies below. A dash means the sources give no information.

What it is

Ganirelix is a synthetic ten-amino-acid peptide, a modified version of gonadotropin-releasing hormone (GnRH) with several unnatural amino acids substituted so that it binds the GnRH receptor without activating it. It was developed by Organon and approved in 1999. The brand name Antagon was dropped; the product is now sold as generic ganirelix acetate injection and as Fyremadel. ¹³⁴

It is used only in assisted reproduction. During ovarian stimulation with injectable follicle-stimulating hormone, rising estrogen can trigger the pituitary to release a surge of luteinizing hormone (LH) that causes ovulation before the eggs can be retrieved. Ganirelix prevents that surge. ⁴

How it works

The pituitary releases LH and FSH in response to pulses of GnRH from the hypothalamus. Ganirelix competes with GnRH for its receptor on pituitary cells and blocks it, so LH secretion falls within hours of the first injection. This is the opposite approach to GnRH agonists such as leuprolide, which first overstimulate the receptor and then exhaust it over one to two weeks. Because the antagonist acts immediately, it can be started partway through stimulation and stopped the day of the ovulation trigger, and its effect reverses quickly. ²⁴

What human research shows

The North American phase 3 trial randomized 313 women at IVF centers to ganirelix, started during stimulation, or to leuprolide, started in the cycle before. Clinical pregnancy rates per attempt were 35.4% with ganirelix and 38.4% with leuprolide, and ongoing pregnancy rates 30.8% and 36.4%; the differences were not statistically significant. Ganirelix cycles were shorter, used fewer injections and yielded slightly fewer eggs (11.6 versus 14.1 on average). Moderate and severe injection-site reactions were less common with ganirelix. ²

The prescribing information summarizes two further trials: a double-blind dose-finding study in 332 women and an open-label randomized study in which 463 women received ganirelix, with a GnRH agonist as the reference treatment. Antagonist protocols built around ganirelix or cetrorelix have since become the default in most IVF programs, partly because they allow a GnRH agonist to be used as the ovulation trigger, which sharply reduces the risk of ovarian hyperstimulation syndrome. ⁴

Study	Model	Finding
North American Ganirelix Study Group	Humans, n=313, randomized open-label phase 3, ganirelix vs leuprolide in IVF	Ongoing pregnancy rates of 30.8% versus 36.4% were not significantly different; ganirelix cycles were shorter with fewer injections. ²
Ganirelix acetate prescribing information	FDA label	Approved to inhibit premature LH surges in controlled ovarian stimulation; abdominal pain, headache and ovarian hyperstimulation syndrome were among the most frequent adverse events in trials. ⁴

Safety

In the label's pooled trial data (794 women), the most frequent adverse events were gynecological abdominal pain (4.8%), fetal death (3.7%, reflecting early pregnancy loss after IVF), headache (3.0%) and ovarian hyperstimulation syndrome (2.4%); injection-site reactions were reported in 1.1%. Ganirelix is contraindicated in pregnancy and in women with hypersensitivity to GnRH analogs, and the label warns of possible allergic reactions including anaphylaxis after the first dose. An observational study of more than 1,000 newborns found congenital anomaly rates after ganirelix cycles comparable with historical controls from agonist cycles. Ovarian hyperstimulation syndrome remains a risk of the stimulation itself, not of ganirelix specifically. ¹⁴

Questions for your clinician

How does the antagonist protocol compare with the long agonist one for my case?
What are the signs of ovarian hyperstimulation I should report?
How many fewer eggs might I expect, and does it matter for my plan?

Questions people ask

Is ganirelix FDA-approved?

Yes, since 1999, for preventing premature LH surges in women undergoing controlled ovarian stimulation. It is sold as ganirelix acetate injection and as Fyremadel. ¹³

How does ganirelix differ from leuprolide in IVF?

Leuprolide is a GnRH agonist that takes one to two weeks to shut down the pituitary and is started the cycle before. Ganirelix is an antagonist that works within hours, so it is started mid-stimulation for a few days. Pregnancy rates were similar in the randomized trial. ²

Does ganirelix reduce the number of eggs?

In the North American trial the ganirelix group averaged 11.6 eggs retrieved versus 14.1 with leuprolide, without a significant difference in pregnancy rates. ²

Is ganirelix the same as cetrorelix?

They are different molecules with the same mechanism, both GnRH antagonists approved for the same IVF use. Trials have not shown a meaningful difference between them. ⁴

Citations

Fyremadel (ganirelix acetate) prescribing information drugs.com
Fluker 2001, Fertility and Sterility: efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation (North American Ganirelix Study Group) doi.org
Organon: ganirelix acetate injection product page organonpro.com
Organon: ganirelix acetate injection prescribing information organon.com